Halozyme Therapeutics Inc (NASDAQ:HALO)
| 26.26 Delayed Data As of Sep 30 |  -0.25 / -0.94%Today’s Change | 12.71 Today|||52-Week Range 29.77 | +48.11% Year-to-Date |
Latest HALO News | Press Releases
| Wall Street Breakfast: The Week Ahead Sep 06 / Seeking Alpha - Paid Partner Content | Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop Sep 05 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 26.51 |
| Today’s open | 26.58 |
| Day’s range | 26.08 - 26.81 |
| Volume | 45,505 |
| Average volume (3 months) | 1,161,506 |
| Market cap | $3.5B |
Data as of 4:00pm ET, 09/30/2020
Growth & Valuation
| Earnings growth (last year) | +10.53% |
| Earnings growth (this year) | +238.50% |
| Earnings growth (next 5 years) | +56.50% |
| Revenue growth (last year) | +29.06% |
| P/E ratio | NM |
| Price/Sales | 13.06 |
| Price/Book | 38.06 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BLUEbluebird bio Inc | -1.05 | -1.91% |
| TWSTTwist Bioscience Cor... | -2.77 | -3.52% |
| FATEFate Therapeutics In... | +0.67 | +1.70% |
| DNLIDenali Therapeutics ... | -0.43 | -1.18% |
Data as of 3:59pm ET, 09/30/2020
Financials
| Next reporting date | November 10, 2020 |
| EPS forecast (this quarter) | $0.20 |
| Annual revenue (last year) | $196.0M |
| Annual profit (last year) | -$72.2M |
| Net profit margin | -36.86% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
Forecasts
